Drugs for dengue: a patent review (2010 – 2014)

Beesetti, Hemalatha ; Khanna, Navin ; Swaminathan, Sathyamangalam (2014) Drugs for dengue: a patent review (2010 – 2014) Expert Opinion on Therapeutic Patents, 24 (11). pp. 1171-1184. ISSN 1354-3776

Full text not available from this repository.

Official URL: http://www.tandfonline.com/doi/abs/10.1517/1354377...

Related URL: http://dx.doi.org/10.1517/13543776.2014.967212


Introduction: Almost half the global population is estimated to be at risk of contracting dengue infection. Of the 400 million infections estimated to occur annually, 4 million can be potentially life-threatening leading to vascular leakage and shock. The only treatment available to severe dengue patients is fluid replacement therapy and supportive care. A drug for treating dengue is an urgent need. Areas Covered: This article endeavors to provide an overview of the experimental dengue drugs being developed around the world as reflected in the recent patent literature spanning the last few years (2010–2014). Expert Opinion: Dengue drug development is essentially in its infancy and currently hobbled by multiple factors including a poor understanding of the molecular mechanism of severe disease and lack of reliable small animal model for preclinical drug evaluation. More intense R&D coupled to setting up product development partnerships to facilitate the efficient movement of a drug molecule from the laboratory to the clinic is needed to make antiviral therapy for dengue a reality in the coming future.

Item Type:Article
Source:Copyright of this article belongs to Taylor & Francis Group.
Keywords:Dengue Antiviral; Entry Blocker; Herbal Antiviral; NS3 Protease Inhibitor
ID Code:109026
Deposited On:09 Mar 2018 12:10
Last Modified:09 Mar 2018 12:10

Repository Staff Only: item control page